Skip to content

NeoGenomics NEO Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

Guardant Health logo
Guardant HealthGH
$1.5B+34.7%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$199.28M-14.7%
Opko Health logo
Opko HealthOPK
$87.38M+13.1%

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.79B+98.5%
Enterprise value$1.71B+177%
P/S2.4×+1.1×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's convertible debt (non-current)?
NeoGenomics (NEO) reported convertible debt (non-current) of $342.24M in Q1 2026.
How has NeoGenomics's convertible debt (non-current) changed year-over-year?
NeoGenomics's convertible debt (non-current) increased by 0.4% year-over-year, from $340.71M to $342.24M.
What is the long-term trend for NeoGenomics's convertible debt (non-current)?
Over 5 years (2020 to 2025), NeoGenomics's convertible debt (non-current) has grown at a 15.3% compound annual growth rate (CAGR), from $168.12M to $341.86M.
What does convertible debt (non-current) mean?
This represents the principal amount of convertible debt obligations that are due beyond one year from the balance sheet date. These instruments provide long-term capital while offering the potential for conversion into equity, which can influence future capital structure and shareholder dilution. Analyzing this metric helps investors evaluate the company's long-term leverage profile and the potential for future equity issuance upon conversion.